Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
20 Jan 2005 -
Amylin Pharmaceuticals, Inc. announced that it has filed a preliminary prospectus supplement to its shelf registration statement with the Securities and Exchange Commission relating to a proposed underwritten public offering of 6.5 million shares of its common stock. To the extent that the underwriters sell more than 6.5 million shares, the company also will grant an over- allotment option to the
underwriters for the purchase of up to an additional 975,000 shares of common stock. All of the shares are being sold by Amylin Pharmaceuticals.
Additional information
Amylin Pharmaceuticals, Inc. San Diego, California, United States of America
Top
Print version
PDF version
Send article
RSS-Feed